Global and China Cancer Tubulin Inhibitors Market Research by Company, Type & Application 2013-2025

Table of Contents

1 Market Overview

• 1.1 Market Segment Overview
  • 1.1.1 Product Definition
  • 1.1.2 Market by Type
    • 1.1.2.1 Docetaxel
    • 1.1.2.2 Trastuzumab Emtansine
    • 1.1.2.3 Abraxane
    • 1.1.2.4 Brentuximab Vedotin
    • 1.1.2.5 Cabazitaxel
  • 1.1.3 Market by Application
    • 1.1.3.1 Non Small Cell Lung Cancer
    • 1.1.3.2 Prostate Cancer
    • 1.1.3.3 Breast Cancer
    • 1.1.3.4 Colorectal Cancer
    • 1.1.3.5 Ovarian Cancer
• 1.2 Global and Regional Market Size
  • 1.2.1 Global Overview
  • 1.2.2 China Overview

2 Global and Regional Market by Company

• 2.1 Global
  • 2.1.1 Global Sales by Company
  • 2.1.2 Global Price by Company
• 2.2 China
  • 2.2.1 China Sales by Company
  • 2.2.2 China Price by Company

3 Global and Regional Market by Type

• 3.1 Global
  • 3.1.1 Global Sales by Type
  • 3.1.2 Global Price by Type
• 3.2 China
  • 3.2.1 China Sales by Type
  • 3.2.2 China Price by Type

4 Global and Regional Market by Application

• 4.1 Global
  • 4.1.1 Global Sales by Application
  • 4.1.2 Global Price by Application
• 4.2 China
  • 4.2.1 China Sales by Application
  • 4.2.2 China Price by Application

5 Regional Trade

• 5.1 Export
• 5.2 Import

6 Key Manufacturers

• 6.1 Abraxis Biosciences
  • 6.1.2 Company Information
  • 6.1.2 Product Specifications
  • 6.1.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
• 6.2 Agensys
  • 6.2.1 Company Information
  • 6.2.2 Product Specifications
  • 6.2.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
• 6.3 Amgen
  • 6.3.1 Company Information
  • 6.3.2 Product Specifications
  • 6.3.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
• 6.4 Celgene
  • 6.4.1 Company Information
  • 6.4.2 Product Specifications
  • 6.4.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
• 6.5 Eagle Pharmaceuticals
  • 6.5.1 Company Information
  • 6.5.2 Product Specifications
  • 6.5.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
• 6.6 Endocyte
  • 6.6.1 Company Information
  • 6.6.2 Product Specifications
  • 6.6.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
• 6.7 Genentech
  • 6.7.1 Company Information
  • 6.7.2 Product Specifications
  • 6.7.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
• 6.8 Immunogen
  • 6.8.1 Company Information
  • 6.8.2 Product Specifications
  • 6.8.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
• 6.9 Modra Pharmaceuticals
  • 6.9.1 Company Information
  • 6.9.2 Product Specifications
  • 6.9.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
• 6.10 Pierre Fabre
  • 6.10.1 Company Information
  • 6.10.2 Product Specifications
  • 6.10.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
• 6.11 Roche
• 6.12 Sanofi-Aventis
• 6.13 Seattle Genetics
• 6.14 Tocris Bioscience

7 Industry Upstream

• 7.1 Industry Chain
• 7.2 Raw Materials

8 Market Environment

• 8.1 SWOT
• 8.2 Porter's Five Forces

9 Conclusion